Neoadjuvant Docetaxel in Breast Cancer: 3-Year Survival Results from the Aberdeen Trial
- 1 October 2002
- journal article
- clinical trial
- Published by Elsevier in Clinical Breast Cancer
- Vol. 3, S69-S74
- https://doi.org/10.3816/cbc.2002.s.015
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Preoperative Chemotherapy in Primary Operable Breast Cancer: Results From the European Organization for Research and Treatment of Cancer Trial 10902Journal of Clinical Oncology, 2001
- Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: A unicentre randomized trial with a 124-month median follow-upAnnals of Oncology, 1999
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Primary chemotherapy in surgically resectable breast cancerCA: A Cancer Journal for Clinicians, 1995
- Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6European Journal Of Cancer, 1994
- Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancerAnnals of Oncology, 1994
- Primary Chemotherapy To Avoid Mastectomy in Tumors With Diameters of Three Centimeters or MoreJNCI Journal of the National Cancer Institute, 1990
- Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancerCancer, 1990
- Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapyCancer, 1988
- Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancerCancer Chemotherapy and Pharmacology, 1978